I am a
Home I AM A Search Login

Papers of the Week

Papers: 1 Jun 2019 - 7 Jun 2019

Human Studies, Pharmacology/Drug Development

2019 Sep

J Pain Symptom Manage



Cebranopadol, a novel first-in-class analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks.


Koch DE, Kapanadze S, Eerdekens M-H, Kralidis G, Letal J, Sabatschus I, Ahmedzai SH
J Pain Symptom Manage. 2019 Sep; 58(3):390-399.
PMID: 31152783.


Pain is one of the most prevalent symptoms associated with cancer. Strong opioids are commonly used in the analgesic management of the disease, but carry the risk of severe side effects. Cebranopadol is a first-in-class drug candidate, combining nociceptin/orphanin FQ peptide and opioid peptide receptor agonism. For cancer patients, frequently experiencing multimorbidities and often exposed to polypharmacy, cebranopadol is easy to handle given its once-daily dosing, the small tablet size that enables swallowing, and the option to flexibly titrate to an effective dose.